Byung Hyun Byun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Byung Hyun Byun has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Byung Il Kim
Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul 07812, Republic of Korea
1 shared publication - Chang Woon Choi
Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
1 shared publication - Choong Mo Kang
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
1 shared publication - Hwan-Jeong Jeong
Department of Nuclear Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Cyclotron Research Center, Molecular Imaging and Therapeutic Medicine Research Center, Jeonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, Republic of Korea
1 shared publication - Hyun-Ah Kim
Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
1 shared publication - Ilhan Lim
Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Breast Cancer
- Vol. 25 (1) , 69-73
The Prediction of HER2-Targeted Treatment Response Using 64Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report
Lee I, et al. J Breast Cancer. 2022 Feb;25(1):69-73. https://doi.org/10.4048/jbc.2022.25.e5
- 1 January 2022
- Published by XMLink in Journal of Breast Cancer
- Vol. 25 (1) , 69-73
Open AccessThe Prediction of HER2-Targeted Treatment Response Using 64Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report
Lee I, et al. J Breast Cancer. 2022 Feb;25(1):69-73. https://doi.org/10.4048/jbc.2022.25.e5
- Open Access
- 23 August 2021
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 55 (5) , 203-209
KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future
This year, the Korean Society of Nuclear Medicine (KSNM) is celebrating its 60th anniversary. Treatment, as well as diagnosis, has played a very important role in the development of nuclear medicine. Since I-131 was used for thyroid therapy in 1959, other radionuclide therapy is still being used, and attempts to use new radionuclide are increasing. In this review, we briefly summarize and introduce the therapies such as radioimmunotherapy, transarterial radioembolization, radionuclide therapy for neuroendocrine tumors, peptide receptor radionuclide therapy, control of metastatic bone pain, radiation synovectomy, radionuclide brachytherapy, alpha particle therapy, and boron neutron capture therapy, which has been being attempted so far in the field of nuclear medicine.
- 23 August 2021
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 55 (5) , 203-209
Open AccessKSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future
This year, the Korean Society of Nuclear Medicine (KSNM) is celebrating its 60th anniversary. Treatment, as well as diagnosis, has played a very important role in the development of nuclear medicine. Since I-131 was used for thyroid therapy in 1959, other radionuclide therapy is still being used, and attempts to use new radionuclide are increasing. In this review, we briefly summarize and introduce the therapies such as radioimmunotherapy, transarterial radioembolization, radionuclide therapy for neuroendocrine tumors, peptide receptor radionuclide therapy, control of metastatic bone pain, radiation synovectomy, radionuclide brachytherapy, alpha particle therapy, and boron neutron capture therapy, which has been being attempted so far in the field of nuclear medicine.